European Agency Says AstraZeneca Use Amid
European Agency Says AstraZeneca Use Amid. In an interview published on Sunday, a senior official of the European Medicines Agency stated that it may be worthwhile to phase out AstraZeneca’s coronavirus vaccine for all ages when alternatives are available. Marco Cavaleri, head of EMA’s vaccination strategy, also told the Italian newspaper La Stampa that Johnson & Johnson vaccines are best used for people over 60 years of age.
Both vaccines are called viral vectors and are legal for anyone over the age of 18, but there are reports of rare blood clots. The European Union has also approved two mRNA vaccines, Pfizer/BioNTech and Moderna. Fearing increased health risks for very young people, Italy on Saturday restricted AstraZeneca’s vaccine to people over 60 years of age.
When asked if it would be better to ban AstraZeneca for people over 60, Cavalleri said: “Yes, given the increasing availability of mRNA vaccines, this is a type that many countries such as France and Germany are considering. Choice. “However, incidents after the first dose are very rare. Yes, there are fewer data for the second dose, but everything is going well in the UK (vaccination schedule). He added, “Young people are at reduced risk of disease, and the message to them is that they want to use mRNA vaccines first, but the choice depends on each state.
He pointed out that Johnson & Johnson’s disposable vaccines “have fewer problems than AstraZeneca. …”, although he pointed out that it is used less frequently.”A dose is useful for some hard-to-reach categories, but it is still an adenovirus (vaccine) and is best reserved for people over 60,” he said. Proteins similar to those found in coronaviruses. After subsequent contact with the real virus, the body recognizes the spike proteins and can fight them.
The adenovirus that causes the common cold acts as a “carrier”, sending genetic instructions to human cells.